Insider Trading February 10, 2026

Rapid Micro Biosystems COO Sells Small Stake to Cover Taxes as Revenue Growth Accelerates

John J. Addington disposed of 4,610 shares on Feb. 9; company posts double-digit revenue gains for 2025 amid ongoing cash burn

By Nina Shah RPID
Rapid Micro Biosystems COO Sells Small Stake to Cover Taxes as Revenue Growth Accelerates
RPID

Rapid Micro Biosystems Chief Operating Officer John J. Addington sold 4,610 shares of Class A common stock on February 9, 2026, raising roughly $17,438 to meet tax obligations tied to vested restricted stock units. The company, with a market capitalization of $180.8 million, reported robust year-over-year revenue growth for 2025 but is drawing down cash reserves even while holding more cash than debt. An earnings release is due February 27 and InvestingPro flags the stock as appearing overvalued relative to its Fair Value estimate.

Key Points

  • COO John J. Addington sold 4,610 shares on Feb. 9, 2026, at $3.7827 per share, raising approximately $17,438 to cover tax obligations from vested restricted stock units.
  • After the sale Addington directly holds 257,768 shares, which includes 29,904 shares obtained through the employee stock purchase plan on March 14, 2025.
  • Rapid Micro Biosystems expects roughly $11.3 million in Q4 2025 revenue (up 37% year-over-year) and about $33.6 million for full-year 2025 (up 20% year-over-year); earnings are due Feb. 27.

Rapid Micro Biosystems NASDAQ:RPID Chief Operating Officer John J. Addington completed a sale of 4,610 shares of the company's Class A common stock on February 9, 2026. The shares traded at $3.7827 apiece, producing proceeds of approximately $17,438. According to subsequent pricing, the stock has risen to $4.08 and is part of a year-to-date advance of 40.7%, despite episodes of volatility.

The disposition was carried out to satisfy tax liabilities associated with the vesting of restricted stock units, the company said. After the transaction, Addington retains direct ownership of 257,768 shares of Rapid Micro Biosystems, which includes 29,904 shares acquired under the company’s employee stock purchase plan on March 14, 2025.

Rapid Micro Biosystems has a market valuation of about $180.8 million. The company currently reports a balance sheet with more cash than debt, yet it is described as rapidly burning through its cash reserves. Investors should note the company’s scheduled earnings release on February 27 for further financial detail.

Independent analysis from InvestingPro indicates that Rapid Micro Biosystems appears overvalued against its Fair Value estimate. InvestingPro also provides a deeper Pro Research Report for more than 1,400 U.S. equities for users seeking additional context.

Separately, Rapid Micro Biosystems disclosed revenue expectations for the fourth quarter and full year of 2025 in a company press release. For Q4 2025 the company expects approximately $11.3 million in total revenue, a 37% increase compared with the same period a year earlier. For the full year 2025 the company anticipates revenue of about $33.6 million, representing a 20% increase from 2024.

The company characterized the revenue gains as indicative of expanding operations and market presence. Those figures and the ongoing cash burn will likely be focal points for investors ahead of the upcoming earnings report.


What happened: Rapid Micro Biosystems COO John J. Addington sold 4,610 Class A shares on February 9, 2026, for $3.7827 each, totaling roughly $17,438. The trade was executed to meet taxes tied to vested restricted stock units.

Ownership after the sale: Addington now directly owns 257,768 shares, which includes 29,904 shares from the employee stock purchase plan dated March 14, 2025.

Company financial snapshot: Market capitalization is about $180.8 million; the company holds more cash than debt but is consuming reserves rapidly. InvestingPro's valuation model indicates the stock appears overvalued relative to its Fair Value estimate.

Near-term catalyst: Quarterly earnings are scheduled for February 27.

Risks

  • The company is rapidly burning through cash reserves despite having more cash than debt - this raises funding and liquidity risk for the business and affects healthcare/biotech and capital markets participants.
  • InvestingPro's analysis suggests the stock appears overvalued relative to its Fair Value estimate, introducing valuation risk for equity investors.
  • Market volatility highlighted by recent price swings could affect investor sentiment ahead of the February 27 earnings report, impacting trading in biotech and small-cap equities.

More from Insider Trading

Clean Harbors Director Executes $204,802 Sale as Company Reports Strong Q4 and Pushes M&A Agenda Feb 21, 2026 Clean Harbors Executive Disposes Nearly $1.0M in Stock as Company Posts Strong Q4 Feb 21, 2026 Clean Harbors CFO Disposes $784K in Shares as Company Reports Strong Quarter and Pursues Acquisition Feb 21, 2026 Travelers Executive Vice President Records $1.74 Million Share Sale as Company Posts Strong Quarter Feb 21, 2026 Genasys Director Buys $50,404 of Stock; Company Reports Mixed Q1 Results Feb 21, 2026